Additional Concerns Regarding Children With Coronavirus Disease 2019—Reply | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Sign In
Comment & Response
October 26, 2020

Additional Concerns Regarding Children With Coronavirus Disease 2019—Reply

Author Affiliations
  • 1Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
JAMA Pediatr. 2020;174(12):1218-1219. doi:10.1001/jamapediatrics.2020.2940

In Reply We much appreciated the interest aroused by our systematic review,1 and we thank all the authors for their thoughtful comments about our work. In our analysis, available evidence showed that most children with coronavirus disease 2019 (COVID-19) presented with mild symptoms, if any, and recovered uneventfully. However, 1 infant had a severe presentation and was successfully treated with intensive care, and 1 death was reported.

The research occurred over a brief 3-month period (from December 1, 2019, to March 3, 2020), and the articles were observational designs and came mainly from Chinese reports because European and US studies in children with COVID-19 were not available at the time this review was conducted.

Despite these limitations, accumulating literature confirmed our main findings,2 showing that children and adolescents appeared the least at-risk population for developing critical disease. Once infected, the risk for a child to develop severe disease requiring hospitalization is 25 times lower than in adults (0.1% vs 2.6%), and the risk of death is 500 times lower than in adults (0.001% vs 0.5%), as based on a French study.3 Hypotheses regarding the relative resistance of children to COVID-19 include (1) resistance to the infection, (2) more efficient control of the infection, (3) less intense immunopathologic reaction, and (4) better capacity of tissue repair.2 Bunyavanich et al4 showed age-dependent nasal gene expression of angiotensin-converting enzyme 2, the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for host entry.4 Lower angiotensin-converting enzyme 2 expression in children relative to adults may help explain why COVID-19 is less prevalent in children.

In addition to reported findings, the unprecedented global research effort to better characterize SARS-CoV-2 infection has shed new light on pediatric COVID-19, adding novel insights to initial evidence. As discussed by Chen and Chiu, Salvatore et al, and Zimmerman et al, although most children with COVID-19 present with mild symptoms, severe cases have been reported, and death can occur in all pediatric age ranges.5 Despite the fact that no definite risk groups have been identified in the pediatric population, comorbidities, including obesity, neurologic condition, chronic lung disease, cardiovascular disease, immunosuppression, and overall medical complexity, have been reported in children with severe COVID-19.5 Also, children younger than 1 year are overrepresented in pediatric COVID-19 cohorts, with a higher risk of fatality compared with children older than 1 year2; in this context, as discussed by He and Zhang, further studies need to analyze clinical outcomes in infected neonates.

Moreover, as a confirmation of the broad spectrum of disease caused by SARS-CoV-2, children presenting with a multisystem inflammatory syndrome associated with COVID-19 are also being reported.6 This syndrome, with features similar to Kawasaki disease, underscores the need for a better understanding of SARS-CoV-2 infection’s pathophysiology in children.

We are working on an updated systematic review of SARS-CoV-2 infection in children and adolescents (PROSPERO identifier: CRD42020181640) to fully characterize the clinical and immunologic features of pediatric COVID-19.

Back to top
Article Information

Corresponding Author: Amelia Licari, MD, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Piazzale C. Golgi 19, 27100 Pavia, Italy (amelia.licari@unipv.it).

Published Online: October 26, 2020. doi:10.1001/jamapediatrics.2020.2940

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank Martina Votto, MD, and Ilaria Brambilla, MD, PhD, for their valuable inputs for the preparation of this response letter.

References
1.
Castagnoli  R, Votto  M, Licari  A,  et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review.   JAMA Pediatr. 2020;174(9):882-889. doi:10.1001/jamapediatrics.2020.1467PubMedGoogle Scholar
2.
Fischer  A.  Resistance of children to COVID-19: how?  Mucosal Immunol. Published online May 28, 2020. doi:10.1038/s41385-020-0303-9PubMedGoogle Scholar
3.
Salje  H, Tran Kiem  C, Lefrancq  N,  et al.  Estimating the burden of SARS-CoV-2 in France.   Science. Published online May 13, 2020. doi:10.1126/science.abc3517PubMedGoogle Scholar
4.
Bunyavanich  S, Do  A, Vicencio  A.  Nasal gene expression of angiotensin-converting enzyme 2 in children and adults.   JAMA. Published online May 20, 2020. doi:10.1001/jama.2020.8707PubMedGoogle Scholar
5.
Shekerdemian  LS, Mahmood  NR, Wolfe  KK,  et al; International COVID-19 PICU Collaborative.  Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units.   JAMA Pediatr. Published online May 11, 2020. doi:10.1001/jamapediatrics.2020.1948PubMedGoogle Scholar
6.
Verdoni  L, Mazza  A, Gervasoni  A,  et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.   Lancet. 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-XPubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×